Peptides and Sleep-Wake Biology
Sleep is controlled not by a single molecular pathway but by the interaction of neural, endocrine and circadian systems. Neuropeptides are included in this network and have the ability to affect neuronal activity, arousal states, hormone secretion and communication between different areas of the brain.
Peptides have therefore been the subject of investigation in the field of sleep research, but they do not all exercise their action via the same mechanism. DSIP, which is known as delta sleep-inducing peptide, has been studied with regard to EEG activity and sleep architecture. GHRH, or growth hormone-releasing hormone, is involved in both endocrine regulation and in sleep-related signalling. Orexin A and orexin B are neuropeptides located in the hypothalamus and play an important role in keeping wakefulness going.
These examples illustrate why “sleep peptides” is not a single pharmacological category. The molecular identity, receptor system, anatomical distribution and experimental endpoint all need to be considered separately.
What Is Sleep Architecture?
Sleep architecture describes the organisation of sleep across different physiological states.
Human sleep is broadly divided into non-rapid eye movement sleep and rapid eye movement sleep. NREM sleep contains several stages that differ in EEG characteristics, arousal threshold and physiological activity. REM sleep has a distinct electrophysiological pattern and is associated with characteristic changes in muscle tone and brain activity.
Experimental sleep research therefore does not rely on total sleep time alone.
Researchers can measure sleep latency, wake time after sleep onset, NREM duration, REM duration, stage transitions, sleep efficiency and EEG power across different frequency bands.
These measurements provide different information. A compound that changes total sleep time, for example, has not necessarily altered the distribution of NREM and REM sleep.
Delta Sleep-Inducing Peptide and EEG Research
DSIP is a synthetic nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu.
The peptide was originally isolated during experiments investigating sleep-associated changes in rabbits. Early work characterised DSIP through amino acid sequencing and examined its effect on EEG activity. The original experiments reported enhancement of delta and spindle-related EEG patterns under the specific conditions used.
Later animal studies looked into whether DSIP could affect the power spectra of the EEG and sleep-related activity. A study involving rats carried out in 2000 found that delta-range EEG activity increased after experimental DSIP exposure.
It is for these findings that DSIP has become an experimental model used in the study of the relationship between peptide structure and sleep-related electrophysiology.
They do not, however, establish a simple mechanism in which DSIP directly controls human sleep.
DSIP and Sleep Architecture
A useful distinction in DSIP research is the difference between EEG activity and sleep architecture.
EEG measurements describe electrical activity in the brain, while sleep architecture describes the organisation and duration of physiological sleep states.
Animal studies have examined both. Human investigations have also used polysomnography to evaluate sleep-stage changes under controlled experimental conditions.
One double-blind study involving chronic insomnia reported some changes in sleep efficiency and sleep latency, but the investigators described the statistically significant effects as weak and noted that several other measures did not change.
Another controlled study found changes in NREM and stage 2 sleep but concluded that the overall effect had little clinical significance.
This variation is important when interpreting the DSIP literature. Different study populations, experimental designs, endpoints and analysis methods can produce different results.
Why the DSIP Literature Remains Difficult to Interpret
DSIP has an unusually long research history, but its precise physiological role remains unresolved.
A later review questioned whether DSIP itself should be regarded as an established endogenous sleep-regulating factor. The authors noted uncertainty surrounding its natural occurrence, biological activity and relationship to sleep regulation.
Structure-activity studies also demonstrate why peptide identity matters. Investigators have tested modified DSIP analogues and observed biological effects that differed from the parent peptide. Changes in amino acid sequence can influence conformation, proteolytic stability, biological distribution and activity.
It therefore follows that findings obtained using a DSIP analogue cannot be automatically assigned to unmodified DSIP.
GHRH and the Relationship Between Sleep and Endocrine Signalling
GHRH serves as another example of the role of peptides in sleep research.
GHRH is a peptide found in the hypothalamus which causes the release of growth hormone by means of the GHRH receptor; research has also examined the relationship between GHRH signalling and the regulation of sleep.
Experimental studies have shown that there is an interaction between GHRH and sleep, especially during NREM sleep. Moreover, research has found an interaction between GHRH and corticotropin-releasing hormone, showing that signals relating to the endocrine system can affect those related to sleep.
The relationship is complex not merely in a linear way.
The relationship between GHRH signalling and sleep can be affected by factors such as sex, age, endocrine status and sleep deprivation, and as a result the findings from human studies cannot be simplified to the notion that increased GHRH activity automatically leads to a specific sleep phenotype.
GHRH, Growth Hormone and Sleep Are Not the Same Endpoint
The fact that GHRH is related to sleep shows once again the need for researchers to distinguish between upstream signalling and downstream endocrine measurements.
GHRH has an effect on the secretion of growth hormone by the pituitary, while sleep is itself controlled by a number of neural circuits. Altering the level of growth hormone experimentally does not necessarily imply that the architecture of sleep has changed.
Research involving humans shows this distinction. It has been reported that the administration of growth hormone systemically had no effect on the total amount of sleep or on the distribution of the various sleep stages, whereas GHRH increased the secretion of growth hormone at night without affecting sleep under the conditions examined.
This offers a valuable lesson with regard to methodology: hormonal measurements and polysomnographic measurements should be considered as distinct endpoints.
Orexin and Wakefulness Signalling
Orexin A and orexin B are neuropeptides located in the hypothalamus and play an important role in the control of wakefulness.
The neurons which produce orexin are mainly found in the lateral hypothalamus but send out their projections to many parts of the central nervous system; their activity interacts with the monoaminergic and cholinergic systems responsible for maintaining arousal.
Orexin signalling occurs via two receptors, OX1R and OX2R. Even though these receptors have overlapping functions, their distributions and signalling properties are not the same.
Research involving both animals and humans has shown a close link between impaired orexin signalling and instability of sleep-wake states. As a result, experimental models make use of the biology of orexin receptors in order to examine how the brain moves from a state of wakefulness through to NREM sleep and then to REM sleep.
Orexin research is therefore especially valuable for gaining an understanding of the neural control of wakefulness rather than viewing orexin as just another peptide associated with sleep.
Neuropeptide Networks in Sleep Regulation
The control of sleep and waking is the result of several neuropeptide systems which may have opposite or overlapping effects.
Reviews of the biology of sleep neuropeptides have regarded orexin as a major regulator of wakefulness, and other neuropeptides—such as galanin, melanin-concentrating hormone and vasoactive intestinal peptide—have been studied in connection with the regulation of sleep and of the REM state. Likewise, neuropeptide Y and substance P are also capable of having context-dependent effects on arousal and on behaviours related to sleep.
This network structure makes it difficult to interpret a peptide in isolation.
Neurons which release a certain peptide might also release other neurotransmitters or co-transmitters and receptor expression can differ from one area of the brain to another with the same signalling molecule producing different effects according to the circuit in which it functions.
Measuring Sleep in Peptide Research
The study of sleep can make use of objective physiological measurements.
By using EEG together with other measurements, polysomnography is able to detect the different sleep stages and the transitions between them. The EEG spectral analysis can then look at the activity in various frequency bands, such as delta, theta, alpha and other frequency ranges that are relevant from an experimental point of view.
Researchers can also determine hormone concentrations, receptor expression, neuronal activity, or gene expression and signalling proteins.
The endpoint chosen should match the research question.
A study concerned with sleep architecture ought not to base itself solely on a measurement of a circulating hormone. In the same way, an experiment involving receptors does not always show a change in sleep behaviour.
Consequently, the best experimental designs link molecular measurements with physiological endpoints that have been properly chosen.
Experimental Models Used in Peptide Sleep Research
Animal models are still important since sleep architecture and neuropeptide systems can be investigated under highly controlled conditions.
Rodent studies have been especially significant in the investigation of orexin neuron activity, receptor signalling and changes in EEG. With the use of genetic models it is possible to eliminate or alter specific receptors or signalling components, thus enabling scientists to assess whether a particular pathway is necessary for a given sleep-wake state.
In the past, research into DSIP has involved the use of rabbits and rats, with EEG serving as the main experimental endpoint. The initial studies also looked at synthetic analogues in order to find out how structural changes influenced electrophysiological activity.
Human studies offer a different kind of evidence since sleep can be assessed by means of polysomnography under controlled conditions. The older peptide studies, though, often had small sample sizes and involved considerably different experimental designs, which made it difficult to carry out a direct comparison.
Limitations of Current Peptide Sleep Research
The research on sleep peptides has some important limits.
Several of the early DSIP studies are more than fifty years old, and later research has led to conflicting interpretations. The human studies have employed relatively small groups of participants and a variety of methods, whereas the findings from animal studies do not always translate directly to human sleep physiology.
GHRH research is just as complex since its effects on the endocrine system and sleep can differ depending on the biological context.
Research into orexin has a more solid mechanistic basis for understanding wakefulness, yet in this area as well the system interacts with various neurotransmitter and neuropeptide networks.
The fact that there are such limitations does not render the research uninformative; instead, the findings should be understood in light of the particular peptide, receptor, model, and endpoint rather than being summed up under a general assertion that they improve sleep.
Peptides as Models for Sleep-Wake Research
The reason why peptide research is scientifically valuable with regard to sleep is that it enables the examination of specific elements of sleep-wake regulation.
DSIP offers a model for the study of peptide structure and EEG activity. GHRH links hypothalamic peptide signalling with endocrine and sleep physiology. Orexin provides a well-characterised system for the investigation of wakefulness and state stability.
These research systems deal with different biological questions.
It is more useful to understand the differences than to regard peptides as a single category meant for producing a specific sleep outcome.
Research Use Only
This article's information is for use in scientific and laboratory research only and is not meant to be used for the diagnosis, treatment, prevention, or management of any disease or condition.
When interpreting the published findings, due account should be taken of the experimental model, the identity of the peptide, the study design and the endpoints that were reported in the original research.
The research materials must be assessed on the basis of their stated chemical identity and analytical specifications rather than on claims that are aimed at consumers regarding sleep quality or other health outcomes.
Anyone who is researching peptide structure, neuropeptide signalling and sleep-wake biology can find further research-use-only materials and technical information.
View research materialsFAQs
References
- Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci U S A. 1977 Mar;74(3):1282-6. doi: 10.1073/pnas.74.3.1282. PubMed ↗
- Schoenenberger GA, Maier PF, Tobler HJ, Wilson K, Monnier M. The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide. Pflugers Arch. 1978 Sep 6;376(2):119-29. doi: 10.1007/BF00581575. PubMed ↗
- Stanojlović OP, Zivanović DP, Susić VT. The effect of delta sleep-inducing peptide on the EEG and power spectra in rat. Indian J Physiol Pharmacol. 2000 Oct;44(4):428-34. PubMed ↗
- Monti JM, Debellis J, Alterwain P, Pellejero T, Monti D. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. Int J Clin Pharmacol Res. 1987;7(2):105-10. PubMed ↗
- Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992;26(4):193-7. doi: 10.1159/000118919. PubMed ↗
- Krueger JM, Obál F Jr, Fang J. Humoral regulation of physiological sleep: cytokines and GHRH. J Sleep Res. 1999 Jun;8 Suppl 1:53-9. doi: 10.1046/j.1365-2869.1999.00009.x. PubMed ↗
- Schüssler P, Yassouridis A, Uhr M, Kluge M, Weikel J, Holsboer F, Steiger A. Growth hormone-releasing hormone and corticotropin-releasing hormone enhance non-rapid-eye-movement sleep after sleep deprivation. Am J Physiol Endocrinol Metab. 2006 Sep;291(3):E549-56. doi: 10.1152/ajpendo.00641.2005. PubMed ↗
- Van Cauter E, Plat L. Physiology of growth hormone secretion during sleep. J Pediatr. 1996 May;128(5 Pt 2):S32-7. doi: 10.1016/s0022-3476(96)70008-2. PubMed ↗
- Sakurai T, Mieda M, Tsujino N. The orexin system: roles in sleep/wake regulation. Ann N Y Acad Sci. 2010 Jul;1200:149-61. doi: 10.1111/j.1749-6632.2010.05513.x. PubMed ↗